Multicenter Alzheimer’s trials are notoriously difficult — especially first-in-human studies involving patients with cognitive impairment and complex PK sampling requirements. But when a sponsor needed to run a seven-cohort study with evolving biomarker needs, tight deadlines, and 17 activated sites, Clinilabs delivered.
In this case study, see how Clinilabs successfully supported a multisite Alzheimer’s trial by:
- Activating sites and enrolling the first subject in just nine days
- Navigating eight protocol amendments, including the addition of CSF sampling
- Delivering top-line results six days post-LPLV
- Achieving high-quality data across all
With indication-level expertise, daily sponsor collaboration, and centralized data capture, Clinilabs kept the trial on track from first patient in to database lock, helping the sponsor validate an amyloid-directed therapy for future development.
